Connect your AI

Royalty Pharma RPRX Investing Cash Flow

Investing Cash Flow at other companies

Ligand PharmaceuticalsLGND

-$94.35M-2,028%

BridgeBio PharmaBBIO

-$42.74M-2,579%

Rigel PharmaceuticalsRIGL

-$7.98M+24.4%

Roivant SciencesROIV

-$1.09B-112,409%

ALN

Alnylam PharmaceuticalsALNY

-$363.46M-157%

Ionis PharmaceuticalsIONS

$23.5M+120%

Other financials

Income statement

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

Operating cash flow$718.2M+20.5%

Valuation

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Royalty Pharma's investing cash flow?: Royalty Pharma (RPRX) reported investing cash flow of -$477.87M in Q1 2026.
How has Royalty Pharma's investing cash flow changed year-over-year?: Royalty Pharma's investing cash flow decreased by 194.8% year-over-year, from $503.92M to -$477.87M.
What is the long-term trend for Royalty Pharma's investing cash flow?: Over 3 years (2021 to 2025), Royalty Pharma's investing cash flow has grown at a -6.8% compound annual growth rate (CAGR), from -$2B to -$1.61B.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.